Info

The Revised Authoritative Guide To Vaccine Legal Exemptions

Vaccines Have Serious Side Effects

Get Instant Access

Barker E, Reisfeld RA (1993) A mechanism for neutrophil-me-diated lysis of human neuroblastoma cells. Cancer Res

53:362-367

Batova A, Kamps A, Gillies SD et al. (1999) The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxi-city in vitro. Clin Cancer Res 5:4259-4263 Batova A, Strother D, Castleberry RP et al. (2002) Immune response to an anti-idiotype monoclonal antibody 1A7 as a tumor vaccine in children with high risk neuroblastoma. Proc Am Assoc Cancer Res 43:143 Bauer M, Reaman GH, Hank JA et al. (1995) A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuro-blastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75:2959-2965 Bauer S, Renner C, Juwana JP et al. (1999) Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res

59:1961-1965

Berthold F, Schumacher R, Schneider A et al. (1989) Removal of neuroblastoma cells from bone marrow by a direct monoclonal antibody rosetting technique. Bone Marrow Transplant 4:273-278

Boerman OC, van Schaijk FG, Oyen WJ et al. (2003) Pretarget-ed radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-411 Bonig H, Laws HJ, Wundes A et al. (2000) In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors. Bone Marrow Transplant 26:91-96 Bowman L, Grossmann M, Rill D et al. (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood

92:1941-1949

Brenner MK, Heslop H, Krance R et al. (2000) Phase I study of chemokine and cytokine gene-modified autologous neuro-blastoma cells treatment of relapsed/refractory neuroblas-toma using an adenoviral vector. Hum Gene Ther 11:1477 Carding SR, Egan PJ (2002) Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2:336-345 Carrel F, Amstutz H, Novak-Hofer I et al. (1997) Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neu-roblastoma. Nucl Med Biol 24:539-546 Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129 Cartron G, Dacheux L, Salles G et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758

Chari RV, Jackel KA, Bourret LA et al. (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 55:4079-4084

Chen S, Caragine T, Cheung NK et al. (2000a) Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Am J Pathol 156:1085-1091 Chen S, Caragine T, Cheung NKV et al. (2000b) CD59 expressed on a tumor cell surface modulates decay-accelarat-ing factor expression and enhanses tumor growth in a rat model of human neuroblastoma. Cancer Res 60:3013-3018 Cheung IY, Cheung NKV (1997) Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 3:821826

Cheung IY, Barber D, Cheung NK (1998) Detection of microscopic neuroblastoma in marrow by histology, immunocy-tology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 4:2801-2805 Cheung IY, Lo Piccolo MS, Kushner BH et al. (2003a) Early molecular response in marrow is highly prognostic following treatment with anti-GD2 and GM-CSF.J Clin Oncol 21:38533858

Cheung IY, Lo Piccolo MS, Kushner BH et al. (2003b) Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21:1087-1093 Cheung N, Landmeier B,Neely J et al. (1986) Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77:739-745 Cheung N, Lazarus H, Miraldi FD et al. (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440 Cheung N, Walter EI, Smith-Mensah WH et al. (1988) Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81:11221128

Cheung N, Lazarus H, Miraldi FD et al. (1992) Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol

10:671-674

Cheung N, Canete A, Cheung IY et al. (1993) Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer

54:499-505

Cheung N, Cheung IY, Canete A et al. (1994) Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 54:2228-2233 Cheung N, Kushner BH, Cheung IY et al. (1998a) Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblas-toma diagnosed at more than 1 year of age. J Clin Oncol 16:3053-3060

Cheung N, Kushner BH, Yeh SD et al. (1998b) 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 12:1299-1306

Cheung N, Yu A (2000) Immunotherapy of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y et al. (eds) Neuroblas-toma. Elsevier, Philadelphia, pp 541-546 Cheung N, Guo HF, Heller G et al. (2000) Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 6:2653-2660 Cheung N, Kushner BH, Kramer K (2001a) Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 15:853-866 Cheung N, Kushner BH, LaQuaglia M et al. (2001b) N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol

36:227-230

Cheung N, Modak S (2002) Oral (1-3,(1-4)-beta-glucan syn-gergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217-1223

Cheung N, Rooney C (2002) Principles of immune and cellular therapy.In: Pizzo PA,Poplack DG (eds) Principles and practice of pediatric oncology, 4th edn. Lippincott, Philadelphia, pp 381-408

Cheung NK, Guo HF, Modak S et al. (2002) Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. Hybrid Hybridomics 21:433-443 Cheung N, Guo HF, Modak S et al. (2003) Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene trans-duction and clonal expansion of human lymphocytes for tumor therapy. Hybrid Hybridom 22:209-218 Cheung N (2004) Therapeutic antibodies and immunologic conjugates.In:Abeloff MD (ed) Clinical oncology.Churchill Livingstone, Edinburgh, pp 661-666 Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM (2004) Single chain Fv-streptavidin substantially improved therapeutic index in multi-step targeting directed at disialoganglioside GD2. J Nucl Med 45:867-877 Colucci F, Caligiuri MA, Santo JP di (2003) What does it take to make a natural killer? Nat Rev Immunol 3:413-425 Coze C, Leimig T, Jimeno MT et al. (2001) Retrovirus-mediated gene transfer of the cytokine genes interleukin-1beta and tumor necrosis factor-alpha into human neuroblastoma cells: consequences for cell line behavior and immunomodulatory properties. Eur Cytokine Netw 12:78-86 Cremonesi M, Ferrari M, Chinol M et al. (1999) Three-step ra-dioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 26: 110-120

Davidoff AM, Kimbrough SA, Ng CY et al. (1999) Neuroblas-toma regression and immunity induced by transgenic expression of interleukin-12. J Pediatr Surg 34:902-907 Davis CA, Gillies SA (2003) Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother

52:297-308

Diefenbach A, Raulet DH (2002) The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 188:9-21 Doubrovina ES, Doubrovin MM, Vider E et al. (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171: 6891-6899

Edwards BS,Nolla HA, Hoffman RR (1992) Resolution of adhesion- and activation-associated components of monoclonal antibody-dependent human NK cell-mediated cytotoxi-city. Cell Immunol 144:55-68 Enomoto A, Kato K, Yagita H et al. (1997) Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice. Cancer Immunol Immunother 44:204210

Evans AE, Main E, Zier K et al. (1989) The effects of gamma interferon on natural killer and tumor cells of children with neuroblastoma. A preliminary report. Cancer 64:1383-1387 Evans AE, August CS, Kamani N et al. (1994) Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. Med Pediatr Oncol 23:323-327 Favrot MC, Michon J, Floret D et al. (1990) Interleukin 2 im-munotherapy in children with neuroblastoma after highdose chemotherapy and autologous bone marrow transplantation. Pediatr Hematol Oncol 7:275-284 Foon KA, Lutzky J, Baral RN et al. (2000) Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.J Clin Oncol 18:376-384 Friedrich SW, Lin SC, Stoll BR et al. (2002) Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 4:449-463 Frost JD, Hank JA, Reaman GH et al. (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus inter-leukin-2 in children with refractory neuroblastoma. Cancer

80:317-333

Geiger JD, Hutchinson RJ, Hohenkirk LF et al. (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513-8519 Goldenberg DM (2003) Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Im-munother 52:281-296 Goldenberg DM, Chang CH, Sharkey RM et al. (2003) Ra-dioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 30:777-780 Goldman A, Vivian G, Gordon I et al. (1984) Immunolocaliza-tion of neuroblastoma using radiolabeled monoclonal antibody UJ13A. J Pediatr 105:252-256

Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20:576-582 Gutheil JC, Campbell TN, Pierce PR et al. (2000) Targeted an-tiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056-3061 Haight AE, Bowman LC, Ng CY et al. (2000) Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Med Pediatr Oncol 35:712-715 Halin C,Neri D (2001) Antibody-Based targeting of angiogen-

esis. Crit Rev Ther Drug Carrier Syst 18:299-339 Handgretinger R, Anderson K, Lang P et al. (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch 14.18 in patients with neuroblastoma. Eur J Cancer 31:261-267

Handgretinger R, Bruchelt G, Schneider M et al. (1987) Application of interleukin 2 in neuroblastoma. Haematol Blood Transfus 31:116-119 Handgretinger R, Baader P, Dopfer R et al. (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199-204 Hank JA, Robinson RR, Surfus J et al. (1990) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res

50:5234-5239

Hank JA, Surfus JE, Gan J et al. (1996) Activation of human effector cells by a tumor reactive recombinant anti-ganglio-side GD2 interleukin-2 fusion protein (ch 14.18-IL2). Clin Cancer Res 2:1951-1959 Heitger A, Ladisch S (1996) Gangliosides block antigen presentation by human monocytes. Biochim Biophys Acta 1303: 161-168

Heuer JG, Tucker-McClung C, Hock RA (1999) Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response. J Im-munother 22:324-335 Hock RA, Reynolds BD, Tucker-McClung CL et al. (1995) Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumori-genicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J Immunother Emphasis Tumor Immunol 17:12-18 Hoefnagel CA, Rutgers M, Buitenhuis CK et al. (2001) A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 28:359-368 Hofheinz RD, Al-Batran SE, Hartmann F et al. (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II Trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44-48

Holzer U, Bethge W, Krull F et al. (1995) Superantigen-staphy-lococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol Immunother 41:129-136 Houghton AN, Mintzer D, Cordon-Cardo C et al. (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242-1246 Huang CS, Utterreuther M, Reisfeld RA (1992) Immunotherapy of GD2+ tumors with a murine monoclonal antibody (MAB) 14G2a; a phase I study. Proc ASCO 11:364 Hugli TE, Muller-Eberhard HJ (1978Anaphylatoxins: C3a and

C5a. Adv Immunol 26:1-53 Ishida H, Matsumura T, Salgaller ML et al. (1996) MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 69:375-380 Jameson J, Witherden D, Havran WL (2003) T-cell effector mechanisms: gammadelta and CD1d-restricted subsets. Curr Opin Immunol 15:349-353 Janeway CA, Travers P, Walport M et al. (2001) Immunobiolo-gy-5: the immune system in health and disease, 5th edn. Garland Publishing, Taylor and Francis Group, New York Juhl H, Petrella EC, Cheung NK et al. (1997) Additive cytotoxi-city of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiolo-

gy 197:444-459

Jurcic JG, Larson SM, Sgouros G et al. (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100:1233-1239

Kawashima I, Tada N, Ikegami S et al. (1988) Mouse monoclonal antibodies detecting disialogangliosides on mouse and human T lymphomas. Int J Cancer 41:267-274 Kemshead JT, Goldman A, Jones D et al. (1985) Therapeutic application of radiolabelled monoclonal antibody UJ13A in children with disseminated neuroblastoma-a phase I study. In: Evans AE, D'Angio GJ, Seeger RC (eds) Advances in neuroblastoma research. Prog Clin Biol Res. Liss, New York, pp

Was this article helpful?

0 0
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment